University Health Network, Osteoporosis Department
Welcome,         Profile    Billing    Logout  
 16 Trials 
8 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cheung, Angela M
NCT01896011: Effect of Teriparatide on Fracture Healing in Patients With Incomplete Atypical Femur Fractures

Completed
3
34
Canada
Teriparatide 20 mcg, Brand name Forteo, Placebo
University Health Network, Toronto, The Physicians' Services Incorporated Foundation, Eli Lilly and Company
Non Displaced Atypical Femoral Fractures
12/21
12/22
PRECIOSA, NCT03451292 / 2016-001789-28: Effects of Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites

Completed
3
410
Europe, Canada, US, RoW
Albutein 20% Injectable Solution, Standard medical treatment
Grifols Therapeutics LLC, Instituto Grifols, S.A.
Decompensated Cirrhosis and Ascites
05/24
05/24
NCT04950127 / 2021-000007-21: Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

Active, not recruiting
3
238
Europe, Canada, Japan, US, RoW
Linerixibat, Placebo
GlaxoSmithKline
Pruritus
10/24
01/25
ESSOR, NCT05999435: Study of LAU-7b for the Treatment of Long COVID in Adults

Active, not recruiting
2/3
272
Canada
LAU-7b for 3 cycles, fenretinide, LAU-7b for 1 cycle, then placebo, Placebo for 3 cycles, sugar pill
Laurent Pharmaceuticals Inc.
Long COVID
08/24
10/24
VISTAS, NCT04663308 / 2020-003027-41: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting
2
200
Europe, Canada, US, RoW
Volixibat, SHP626, Placebo
Mirum Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc.
Primary Sclerosing Cholangitis
09/25
12/25
NCT05231668: Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)

Terminated
1
16
Europe, Canada, US, RoW
SAR439459, Placebo
Sanofi
Osteogenesis Imperfecta
11/24
11/24
NCT01155245: Teriparatide (PTH) and Bone Strength in Postmenopausal Women

Active, not recruiting
N/A
60
Canada
Forteo
University Health Network, Toronto, Eli Lilly and Company
Osteoporosis
01/24
01/25
Cowan, Juthaporn
MOSAIC, NCT04894435: Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity

Active, not recruiting
2
669
Canada
mRNA-1273 SARS-CoV-2 vaccine, COVID-19 Vaccine Moderna, Spikevax, BNT162b2, Pfizer-BioNTech COVID-19 Vaccine, Comirnaty, ChAdOx1-S [recombinant], Astra Zeneca COVID-19 Vaccine, COVISHIELD AstraZeneca COVID-19 Vaccine, Vaxzevria, 0, 28 day schedule, 0, 112 day schedule, Covifenz, Medicago COVID-19 vaccine
Canadian Immunization Research Network, Canadian Center for Vaccinology, BC Children's Hospital Research Institute, Children's Hospital Research Institute of Manitoba, CHU de Quebec-Universite Laval, Ottawa Hospital Research Institute, Ontario Agency for Health Protection and Promotion, University of Toronto, Massachusetts General Hospital, Interior Health, McGill University Health Centre/Research Institute of the McGill University Health Centre
COVID-19
11/24
02/25
Tomlinson, George
No trials found
Cohen, Suzanne
No trials found

Download Options